Abeona Therapeutics Inc
ABEO6.425USD
-0.066-1.01%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
314.50MCap. mercado
PérdidaP/E TTM
Más Datos de Abeona Therapeutics Inc Compañía
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Información de la empresa
Símbolo de cotizaciónABEO
Nombre de la empresaAbeona Therapeutics Inc
Fecha de salida a bolsaSep 19, 1980
Director ejecutivoDr. Vishwas (Vish) Seshadri, Ph.D.
Número de empleados136
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 19
Dirección6555 Carnegie Ave, 4th Floor
CiudadCLEVELAND
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal44103
Teléfono16468134701
Sitio Webhttps://abeonatherapeutics.com/
Símbolo de cotizaciónABEO
Fecha de salida a bolsaSep 19, 1980
Director ejecutivoDr. Vishwas (Vish) Seshadri, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
47.15K
--
Dr. Eric Crombez, M.D.
Dr. Eric Crombez, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph Vazzano, CPA
Mr. Joseph Vazzano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 12 de jul
Actualizado: sáb., 12 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
39.27%
Investment Advisor
9.65%
Investment Advisor/Hedge Fund
6.04%
Individual Investor
5.83%
Venture Capital
4.82%
Research Firm
3.12%
Pension Fund
0.17%
Other
31.08%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
154
35.41M
69.26%
-4.09M
2025Q1
147
35.53M
69.67%
-3.94M
2024Q4
142
35.48M
81.61%
-1.29M
2024Q3
136
33.53M
77.24%
-4.39M
2024Q2
136
35.81M
86.04%
+12.73M
2024Q1
132
18.43M
63.48%
+1.42M
2023Q4
122
17.76M
63.56%
+2.13M
2023Q3
129
13.60M
55.05%
-1.35M
2023Q2
141
10.67M
49.73%
+4.50K
2023Q1
170
7.90M
44.30%
-1.15M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Suvretta Capital Management, LLC
3.69M
7.2%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.51M
6.86%
-19.36K
-0.55%
Mar 31, 2025
Adage Capital Management, L.P.
2.69M
5.26%
-1.21M
-31.03%
Mar 31, 2025
Western Standard, LLC
2.28M
4.46%
+196.78K
+9.44%
Mar 31, 2025
The Vanguard Group, Inc.
2.02M
3.95%
+54.16K
+2.75%
Mar 31, 2025
Vivo Capital, LLC
1.84M
3.6%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
1.81M
3.53%
+427.00
+0.02%
Mar 31, 2025
Laurion Capital Management LP
1.31M
2.55%
--
--
Mar 31, 2025
Armistice Capital LLC
1.30M
2.54%
+1.30M
--
Dec 31, 2023
Seshadri (Vishwas)
1.30M
2.55%
-51.56K
-3.80%
Jun 06, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Simplify Propel Opportunities ETF
4.69%
iShares Neuroscience and Healthcare ETF
0.63%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Ver más
Simplify Propel Opportunities ETF
Proporción4.69%
iShares Neuroscience and Healthcare ETF
Proporción0.63%
iShares Micro-Cap ETF
Proporción0.06%
iShares Russell 2000 Growth ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Fecha
Tipo
Relación
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
